Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $183

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $182 to $183.